High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy
oleh: Moez Dungarwalla, Steve O. Evans, Unell Riley, Daniel Catovsky, Clare E. Dearden, Estella Matutes
| Format: | Article |
|---|---|
| Diterbitkan: | Ferrata Storti Foundation 2008-03-01 |
Deskripsi
The combination of high dose methylprednisolone and rituximab induces superior overall (93%) and complete (14%) response rates compared to high dose methylprednisolone alone (overall 43%, complete remission 0%) in heavily pre-treated chronic lymphocytic leukemia patients with advanced disease. Despite its efficacy the combination is not easily manageable because of the high rate of opportunistic infections.